What changed
$AZN — BUY 📊 | 6 MONTHS THESIS
🎯 latest | Rev $2.7B | EPS $1.29 vs $1.27 🟢
💡 Consensus underestimated core drug revenue growth; our variant view is that sales momentum will persist, leading to EPS upgrades and a re-rating closer to peer growth multiples.
📉 Reward/risk: 2.5:1
🏢 Business Quality: 7/10 - Strong product portfolio and pipeline demonstrated by top-line and bottom-line beat.
📊 Valuation: fair — P/E 34x annualized Q EPS, at premium to large pharma sector (20-25x), but justified by superior growth; DCF suggests slight upside with...
🔮 Catalyst: Next quarterly earnings report and potential pipeline milestones
💰 Entry: $174.93, stop $165, target $200
⚖️ Buy AZN on post-earnings momentum with estimate revision catalyst; target $200, stop $165, 2.5:1 R/R.
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/AZN0620